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Object. Diffusion tensor imaging (DTI) has been shown to detect tumor invasion in glioblastoma 
patients and has been applied in surgical planning. However, the clinical value of the extent of 
resection based on DTI is unclear. Therefore we retrospectively reviewed the correlation 
between the extent of resection of DTI abnormalities and patients’ outcome. 
Methods. We reviewed 31 newly diagnosed supratentorial glioblastoma patients who 
underwent standard 5-ALA aided surgery with the aim of maximal resection of the enhancing 
tumour component. All patients received presurgical MR including volumetric T1 post contrast, 
DTI and FLAIR. Postsurgical anatomical MR images were obtained within 72 hours after 
resection. The diffusion tensor was split into an isotropic (p) and anisotropic (q) component. 
The extent of resection was measured for the abnormal area on the p, q, FLAIR and T1 post 
contrast map. Data were analyzed in relation to patients’ outcome using univariate and 
multivariate Cox regression models controlling for possible confounding factors including age, 
MGMT-methylation status and IDH-1 mutation. 
Results. Complete resection of T1 contrast enhancing tumor was achieved in 24 out of 31 
patients (77%). The mean extent of resection of the abnormal p, q and FLAIR area were 57%, 
83% and 59%, respectively. Increased resection of the abnormal p and q areas correlated 
positively with progression free survival (p = 0.009 and p = 0.006, respectively). Additionally, a 
larger residual q volume predicted significantly shorter time to progression (p = 0.008). More 
extensive resection of the abnormal q and T1 contrast area improved overall survival (p = 
0.041 and p = 0.050, respectively).  
Conclusion. Longer progression free survival and overall survival were seen in glioblastoma 
patients in which more DTI abnormality was resected, previously shown to represent infiltrative 
tumor. This highlights potential usefulness and the importance of an extended resection based 
on DTI-derived maps. 
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INTRODUCTION 
Glioblastoma is the most prevalent malignant primary brain tumors and one of the leading 
cancers in terms of years of life lost.15 Standard treatment against this highly malignant disease 
includes maximal safe resection followed by concomitant chemoradiotherapy (CCRT) and 
adjuvant chemotherapy with temozolomide. However, the prognosis remains poor with two 
and five-year survival only 27% and 9.8%, respectively.27 
 
The main factors influencing prognosis are age, performing status, tumor molecular type and 
extent of resection, of which the former three are fixed while the latter can be changed. 
Therefore, many efforts have been put on the extent of maximal tumor resection while 
preserving normal brain tissue and function. Resection of a larger fraction of the tumor results 
in a longer life expectancy.6,7,12 In order to achieve maximal tumor resection, intraoperative 
neuronavigation, 5-aminolevulinic acid (5-ALA) and other imaging techniques (e.g. 
intraoperative MR or ultrasound) have been introduced. Utilization of 5-ALA increased the 
extent of resection to 65% of the total contrast enhancing area and prolong the progression 
free survival.24 Contrast-enhanced T1-weighted signal has many limitations in accuracy of the 
delineation of tumor margin.19 Consequently, the clinical benefit of resection outside the 
contrast enhanced area has been investigated.13 Recently it has been shown that extending 
the resection to the peritumoral high T2 areas beyond the T1 contrast enhancing can provide 
longer survival than less extensive resections.13 This is thought to be due to tumor infiltration 
beyond the contrast enhancing area.20 However high T2 is not specific for tumor infiltration, as 
it is also caused by edema.  
 
Diffusion tensor imaging (DTI) is able to detect tumor extent beyond the contrast enhancing 
area due to subtle white mater change.17 By decomposing the diffusion tensor into an isotropic 
component (p) and anisotropic component (q),16 white matter that is infiltrated or disrupted by 
the glioblastoma can be identified.17 Radiotherapy treatment plans based on peritumoral 
abnormal DTI areas were able to achieve a large reduction of 15 - 35% in planning target dose 
and 50% of clinical target volume, which minimized radiation complication without affecting the 
survival.1,8 In addition, DTI changes especially, p map, can be used for evaluate early treatment 
response after temozolomide chemotherapy in glioma patients.2 However, to date there are no 
studies showing a clinical benefit of resecting the abnormal peritumoral DTI area. This 
prompted our study to aim at analyzing the influences of the extent of resection of abnormal 





We included 31 glioblastoma patients (mean age 56 years, range 31-68; 19 males) from our 
consecutive cohort. All patients were with a Karnofsky performance score ≥70 and with 
presurgical MR scans that also had follow-up MR available after tumor resection. Patients were 
deemed suitable to undergo complete resection of the contrast enhancing tumor by one senior 
author neurosurgeon (SJP)  and all subsequently underwent tumor resection under 
neuronavigation (StealthStation, Medtronic, Minnesota, USA) and 5-ALA fluorescence 
guidance with the aim of maximal tumor resection. The presurgical images were acquired on 
average one day (range 0-9) before surgery. Follow-up MR scans were obtained as soon as 
possible after surgery and no later than 72 hours. Exclusion criteria were previous cranial 
surgery, previous cerebral radiotherapy or a known other primary tumor. All patients received 
standard concomitant and adjuvant temozolomide chemoradiotherapy27 about one month after 
surgical resection. MGMT is done with pyrosequencing of the DMR2 region. IDH is measured 
using immunohistochemistry for R132H mutation. Survival data were extracted from the 
medical records. Tumor eloquence was classified as described previously.22,12 
The study was approved by the local Institutional Review Board (10/H0308/23) and informed 
written consent was obtained from all patients. 
 
MR data acquisition 
Presurgical imaging was performed on a 3.0 T MR Magnetom system (Siemens Healthcare, 
Munich, Germany) with a standard 12-channel head coil. Imaging included a T1-weighted 
imaging after contrast, T2-weighted fluid attenuated inversion recovery (FLAIR) sequence and 
DTI. A 3D T1-weighted scan with fat suppression was acquired after the intravenous injection 
of 9 mL gadolinium (Gadovist, Bayer Schering Pharma, Berlin, Germany) (TR/TE/TI 
2300/2.98/900 ms; flip angle 9°, FOV 256 × 240 mm; 176-192 slices; no slice gap; voxel size 
of 1 × 1 × 1 mm).  A 2D FLAIR sequence was performed (TR/TE/TI 7840-8420/95/2500 ms; 
flip angle 150°; FOV 250 x 200 mm; 25-27 slices; 1 mm slice gap; voxel size 0.78125 x 0.78125 
x 4 mm). DTI data was acquired using a single-shot echo-planar sequence (TR/TE 8300/98 
ms; flip angle 90°; FOV 192 x 192 mm; 63 slices; no slice gap; voxel size 2 x 2 x 2 mm) with 
multiple b-values (0, 350, 650, 1000, 1300 and 1600 s/mm2) scanned in 13 directions.  
 
Direct postsurgical images were acquired on a 1.5 T GE Optima, a 1.5 or 3.0 T GE Signa or a 
3.0 T GE Discovery (General Electric Company, Little Chalfont, United Kingdom) with standard 
head coil. Imaging included a T1-weighted anatomical sequence after the intravenous injection 
of 9 mL gadolinium (Gadovist, Bayer Schering Pharma, Berlin, Germany). This was performed 
as a 2D T1-weighted sequence (TR/TE 460-700/11-21 ms, flip angle 90°, FOV 220-260 x 220-
260 mm; 20-85 slices; 0-1 mm slice gap; voxel size 0.429-0.5079 x 0.429-0.5079 x 2-6 mm) 
or a 2D T1 inversion recovery sequence (TR/TE/TI 2508-2600/12-42/780-920 ms; flip angle 
90-110°, FOV 220 × 220 mm; 20-22 slices; 1-3.5 mm slice gap; voxel size of 0.4297 x 0.4297 
x 6 mm). 
 
Image processing 
DTI images were processed using tools from the FMRIB Software Library (FSL) version 5.0.0 
(fsl.fmrib.ox.ac.uk/fsl/fslwiki). DTI images were realigned to the b0-image to compensate for 
eddy currents and motion.10 We calculated the isotropic (p) and anisotropic (q) component 
after eigenvalues were calculated on multiple fiber directions at each voxel in the DTI data as 
described previously described.16 For each subject, presurgical DTI and FLAIR images were 
coregistered with presurgical post contrast T1 weighted images by a linear transformation 
using the default FLIRT functions provided by FSL.10  
 
Coregistration between postsurgical and presurgical images was done by a semi-automatic 
co-registration methods (AH and JLY).. All images were fit into presurgical volumetric contrast-
enhanced T1-weighted images. Firstly, we used automatic brain extracted  images,9 which 
were manually corrected. Then we calculated the transformation between presurgical tumor 
and postsurgical resection cavity by using the linear FLIRT co-registration of the lesion, 
ventricle and the external mask of the brain between presurgical and postsurgical images. 
These transformation were then used as input transformation matrix for a non-linear FNIRT 
coregistration to coregister the brain. 
  
Tumor Volume and EOR Data analysis 
Extent of resection was determined by the surgical resection cavity in the coregistered 
postsurgical T1 post contrast (Figure 1, blue outline) by an author (JLY) blinded to the outcome 
at the moment with the agreement of the second author (AH). The 3D peritumoral abnormal 
FLAIR, p and q regions of interest were manually selected on the coregistered presurgical MR 
images (Figure 1B, 1C and 1D, respectively). The interobserver correlation was done between 
the first author (JLY) and senior author (SJP) with fair agreement. The coregistered resected 
region was extracted from the total abnormal presurgical region for each sequence using 
Matlab (MathWorks Inc., Natick, MA, USA). The resected volumes were calculated for the p, 
q and FLAIR regions by multiplying all voxels of interests with the slice thickness in Matlab. 
 
Statistical Analysis 
Data was analyzed using SPSS version 22 (IBM Inc., New York, USA). Cox regression model 
was used to estimate the influence of the extent of resection based on p, q, FLAIR and T1 post 
contrast images on progression free survival and overall survival. Multivariate analysis includes 
the covariates age, O6-methylguanin-DNA-methyltransferase (MGMT) methylation status, 
isocitrate dehydrogenase (IDH)-1 mutation, presurgical tumor volume based on T1 post 
contrast, tumor location based on eloquence and midline shift. These covariates were tested 
individually with resection ratio of p, q, FLAIR, T1 contrast enhancing area and residual tumor 
volume based on different MR images. Subgroup analysis was done for a group with a low and 
high q resection ratio by splitting the patient based on the median of the whole group. Patients’ 
characteristics comparisons in different groups were calculated by using t-test for continuous 
data as they showed a normal distribution tested by D'Agostino-Pearson normality test and the 
chi-square for dichotomous data. Chi square test with Yate’s correction was used for small 





Patients’ clinical characteristics are shown in Table 1. Complete resection based on T1 post 
contrast was achieved in 24 patients (77% out of 31). Ten patients had the tumor located within 
an eloquent area which included primary motor or sensory cortex, speech center, internal 
capsule and basal ganglia. Ten patients had tumor located in near eloquent area which 
included supplementary motor area, near calcarine fissure, near speech center, corpus 
callosum. The mean midline shift was 3.3 mm (SD ± 3.7; range 0-11.9). Mean presurgical T1 
enhancing tumor volume was 46 mL (± 30; range 8-119 mL). Size of resection area was 53 
mL (± 31; range 10-131), which was significantly larger than the presurgical tumor (p = 0.001). 
A total of 57% of the p area, 83% of the q area and 59% of the FLAIR area were resected. 
Residual tumor volume based on p, q, FLAIR and T1 contrast enhanced images were 38.4 mL 
(± 30.2; range 4.4-129.4), 8 mL (± 9.7; range 0-36), 40.7 mL (± 32.7; range 0.4-127.9), and 2.7 
mL (± 6.8; range 0-26.6), respectively. All patients did not have major postsurgical neurologic 
deficit and decrease KPS under 70 which is our condition to enter the following temozolomide 
chemoradiotherapy. 
 
Extent of Resection and Patient Outcome 
Univariate Cox regression models for each variable showed a significant correlation of 
progression free survival with the extent of resection of p (p = 0.030), complete resection of T1 
contrast enhancing lesion (p = 0.004) and MGMT methylation status (p = 0.041). Multivariate 
analysis was used to test extent of resection with other covariables (Table 2).  The results 
showed that resection of the more abnormal p was a protective predictor of tumor progression 
(HR = 0.911, p = 0.009). The extent of resection of q areas was also significant correlate with 
progression free survival in the multivariate analysis (HR = 0.935, p = 0.006). The extent of 
resection of FLAIR showed no association with progression free survival in both univariate and 
multivariate analysis (p = 0.994 and p = 0.799, respectively). Presence of MGMT methylation 
was found to be a significant predictor of progression free survival in the multivariate models 
for p (HR = 4.626, p = 0.009), q (HR = 6.716, p = 0.006) and FLAIR (HR = 95.941, p = 0.001). 
 
For overall survival, multivariate analysis was performed after controlling for the age, MGMT-
methylation status, IDH-1 mutation status, presurgical tumor volume, tumor eloquence and 
midline shift. Extent of resection based on q and T1 contrast were identified as predictors for 
overall survival (HR = 0.965, p = 0.041 and HR = 9.946, p = 0.050, respectively). The MGMT 
methylation status was significantly associated to overall survival in the multivariate models for 
p (HR = 3.737, p = 0.043), q (HR = 4.932, p = 0.012) and FLAIR (HR = 10.274, p = 0.009). 
Besides, presurgical tumor volume based on T1 post contrast was found to be a covariable 
that increase the hazard in extent of resection on q (HR = 1.039, p = 0.024) and T1 contrast 
(HR = 1.037, p = 0.040). 
 
As previous results indicated the importance of the extent of resection especially q abnormality 
on outcome, we explored this in more detail. Classifying patients into two groups by using the 
median of the extent of q resection, resulted in a resection cut-off of 89% of the q abnormality. 
Patients with a resection over 89% of the q abnormality had a significantly longer progression 
free survival (421 ± 311 days) than those with under 89% (257 ± 214 days; p = 0.034) and 
better overall survival (621.9± 389.0 versus 518.13 ± 264.7; p = 0.011; Figure 2). With this two 
subgroups, there was no statistical difference in age, gender, tumor location, number of 
patients receiving a gross-total resection, MGMT methylation or IDH-1 mutation status (Table 
3). Similar result can be seen while subgrouping patient with median extent of p resection, 
longer progression free survival was shown in patients received over 60% of resection on p 
abnormal area. (421 ± 311 versus 258 ± 176, p = 0.046). 
 
In our study, 26 patients (83.9%) had tumor recurrence within 2 cm adjacent to the resection 
cavity. Three patients (9.7%) had distal recurrence more than 2 cm from the original resection 
cavity, and 2 had recurrence both locally and distally. All solely distal recurrence patients 
received complete resection of T1 contrast enhancing lesion and a higher extent of resection 
of q abnormal area (97.7%) versus the others (87.4%) and two of them were MGMT 
methylated. Progression free survival (721 ± 270 days) and overall survival (954 ± 461 days) 
were also longer in distal recurrent patients. 
 
 
Residual Tumor Volume and Patient Outcome 
The correlation of patients’ outcome and residual tumor volume based on different MR images 
are summarized in Table 4. A larger residual volume of DTI showed a decrease in progression 
free survival, which was statistically significant for the q abnormality (HR = 1.118, p = 0.008), 
while residual volume of p was not significant (HR = 1.28, p = 0.074). Residual FLAIR was not 
correlated to progression free survival. Overall survival was not influenced by the residual p, q 
or T1 contrast volume. Residual FLAIR volume decreased the hazard ratio of overall survival 




In this study, we retrospectively review the correlation between the extent of resection based 
on DTI and patients’ outcome. Although the intention of initial surgical resection is based on 5-
ALA rather than on any DTI parameter, this study showed a significant correlation between the 
extent of resection based on both the p map, and q map with progression free survival using a 
multivariate Cox regression model. Furthermore a favorable overall survival can be seen in 
patients received more resection of the q map and T1 contrast enhancement. Thus, by 
resecting more abnormal DTI areas, most importantly the q area, the infiltrating tumor burden 
decreases leading to better outcome.  
 
The significance of resecting more T1 contrast enhanced lesion has been shown clearly to 
correlate with patient survival. Sanai and colleagues showed improved overall survival begins 
starting at a resection of 78% and continue to increase with more tumor resection of the 
contrast enhancing area.21 A non-volumetric studies of high grade glioma has also shown a 
longer overall survival in complete resection than in incomplete resection (16.7 versus 11.8 
months. p < 0.001).25 Others also showed the synergic clinical benefit of the extent of resection 
and concomitant chemoradiotherapy.23 Moreover, the benefit of reduced tumor burden was 
also shown on the efficacy of1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) of where a lower 
concentration is needed to achieve 90% of growth inhibition in low tumor burden groups.14 In 
patients receiving BCNU wafers during surgery, longer median survival is also noted in the 
complete resection group compared to in subtotal resected patients.26 Therefore, reduction of 
enhancing tumor burden is an important prognostic factor for patient outcome.  
 
However, to date, most studies have defined extent of resection using the contrast enhancing 
area only. But, a false negative rate of 16% can be found in normal appearing areas on T1,17 
and tumor cells often extend beyond the contrast enhancing area. We have previously shown 
that specific DTI signatures can predict this microscopic tumor invasion.17,18 In particular, 
regions with >10% increase of the p (isotropic) component signified white matter infiltration by 
tumor, whilst regions with >12% decrease in q (anisotropic) component showed white matter 
disruption by cancer. Therefore, using DTI can better delineate actual tumor margin and show 
the invasive area of tumor. Although, we have not performed a histological correlation in this 
study, previous research has validated a correlation between DTI and viable tumor cells.4 
 
A previously conducted tumor resection treatment bias study showed that complete resection 
more often achieved in younger patients and tumors in non-eloquent tumor location.25 We 
tested our result by using median q extent of resection 89% as the cut-off to stratify patients 
into two group. In these two groups, a longer progression free survival can be seen in those 
receiving more than 89% of q resection, but other variables including age, tumor eloquence, 
MGMT-methylation status, IDH-mutation, midline shift, presurgical tumor size and complete 
T1 contrast resection rate were all comparable (Table 3). A bias could therefore not be 
identified, which strengthens our results indicating the importance of the extent of resection 
based on DTI.  
 
Specifically looking at the distal recurrence patients, previous study showed a correlation 
between extended resection and recurrence pattern with a better prognosis in those with distal 
recurrence3. In our study, all three distal recurrent patients received a higher extent of resection 
on DTI abnormality (EOR of q > 97%) beyond contrast enhanced area. Although the number 
in our study is small, this finding may indicate that distal recurrence occurs in those with a 
better local control based on DTI and consequently resulted in a better prognosis. 
 
 
We also examined the residual tumor volume based on different MR sequences. The more q 
volume left after surgery can significantly increase the risk of progression and marginally 
decrease overall survival. Grabowski and colleagues showed that residual contrast enhanced 
lesion volume more than 2 cm3 after surgical resection was a strong unfavorable predictor to 
overall survival.5 Furthermore, others also concluded that a smaller residual contrast enhanced 
tumor under 10 cm3 can lead to both prolonged time to progression and survival.11 In our results 
only marginal significance in progression free survival was noted based on T1 post contrast. 
This may be due to the limited numbers of patients in our study. Regardless of the limited 
numbers, we clearly displayed the advantage of the q map, which according to a previous 
biopsy studies, represents regions of tumor cells.17 Thus a smaller residual abnormality on the 




In summary, with the expanding application of DTI in brain tumor patients, it can not only 
demonstrate the possible tumor invasion but also provide a guide for surgeons. Our results 
underscore the importance of  abnormal DTI area, especially of abnormal q area, that in 
patients received more extent of resection and with less residual abnormal DTI had better 
patients’ progression free survival and overall survival. Further prospective studies is needed 
to clarify the clinical benefit of incorporating DTI into surgical planning. 
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TABLE 1 - Patient Characteristics 
Total number of patients 31 
Male 19 
Female 12 




Near eloquent 12 
Non eloquent 9 
Midline shift (mm) 3.3 ± 3.7 
Presurgical tumor size (mL) 
 
T1 contras enhanced 46 ± 30 
FLAIR 84 ± 44 
Isotropic (p) DTI 83 ± 44 
Isotropic (q) DTI 51 ± 23 
Extent of resection (%)  
T1 post contrast  136 ± 71 
FLAIR 58 ± 21 
Isotropic (p) DTI 57 ± 18 
Isotropic (q) DTI 83 ± 20 
Residual tumor size (mL)  
       T1 post contrast  2.7 ± 6.7 
FLAIR 41 ± 32 
Isotropic (p) DTI 38 ± 30 
Isotropic (q) DTI 8 ± 9.6 
GTR (based on contrast) 24 
STR (based on contrast) 7 
IDH-1 positive 3 
MGMT methylation positive 10 
Progression free survival (days) 367 ± 263 
Overall survival (days) 559 ± 292 
 
Numbers or mean values and standards deviation are presented for the main patient 
characteristics. Abbreviations: DTI = diffusion tensor imaging; FLAIR = fluid attenuated 
inversion recovery; GTR = gross total resection; IDH-1 = Isocitrate dehydrogenase-1; MGMT 
= O6-methylguanin-DNA-methyltransferase; STR = subtotal resection.  
  
TABLE 2 - Extent of Resection and Patients’ Outcome 
 
Progression Free Survival  Overall Survival 
 
p-value HR CI (95%)  p-value HR CI (95%) 
EOR of p 0.009* 0.911 0.850-0.977  0.795 0.993 0.940-1.049 
EOR of q 0.006* 0.935 0.891-0.980  0.041* 0.965 0.934-0.999 
EOR FLAIR 0.799 0.997 0.926-1.061  0.052 1.062 1.999-1.129 
EOR of T1C 0.094 6.499 0.727-58.069  0.050* 9.946 1.005-98.464 
 
Multivariate analysis results showing age, MGMT methylation status, IDH-1 mutation status, 
presurgical tumor volume based on T1 post contrast, midline shift and tumor eloquent location 
as covariates. An * indicates a statistically significant p-value. Abbreviations: CI = confidence 
interval; EOR = extent of resection; T1C= T1 post contrast; FLAIR = fluid attenuated inversion 











TABLE 3 - Patient characteristics for the subgroups of q resection area 
 
q EOR < 89% q EOR > 89% p-value 
Male 9 10 1 
Female 6 6 
 




Eloquent 5 5 
 
Near eloquent 8 4 
 
Non eloquent 2 7 
 
Midline shift (mm) 3.33 ± 3.90 3.65 ± 3.63 0.8138 
Presurgical tumor size (mL)    
T1 post contrast  35.9 ± 18.4 53.3 ± 30.6 0.0682 
FLAIR 81.1 ± 37.8 95.8 ± 52.2 0.3888 
Isotropic (p) DTI 80.1 ± 38.1 90.9 ± 48.2 0.4948 
Isotropic (q) DTI 48.8 ± 14.3 54.5 ± 30.8 0.5147 
GTR (based on contrast) 9 15 0.0693 
STR (based on contrast) 6 1 
 
IDH-1 positive 2 1 0.5050 
MGMT methylation positive 5 5 0.9013 
Progression free survival (days) 257 ± 214 421 ± 311 0.034* 
Overall survival (days) 518.13 ± 264.7 621.9± 389.0 0.011* 
 
T1C = T1 post contrast. 
Patients’ characteristics are displayed for the subgroup of patient with an extent of resection 
(EOR) over or below 89%. Progression free survival and overall survival comparison were 
analyzed by multivariate Cox regression model. Number or mean and standard deviation are 






Table 4 - Residual Tumor Volume and Patients’ Outcome 
 
Progression Free Survival  Overall Survival 
 
p-value HR CI (95%)  p-value HR CI (95%) 
Residual T1 contrast 0.060 1.393 0.986-1.969  0.401 1.140 0.840-1.549 
Residual p 0.074 1.028 0.997-1.059  0.942 0.999 0.970-1.029 
Residual q 0.008* 1.118 1.029-1.215  0.080 1.053 0.994-1.116 
Residual FLAIR 0.882 1.003 0.968-1.038  0.008* 0.939 0.897-0.983 
 
Multivariate analysis results showing age, MGMT methylation status, IDH-1 mutation status, 
presurgical tumor volume based on T1 contrast imaging, midline shift and tumor eloquent 




FIGURE 1 - Regions of interest and extent of resection 
 
 
Presurgical T1 post contrast (A), FLAIR (B) and DTI (C-D) are shown with the resected area 
contoured on top in blue (A-D) in a representative example of one patient. The abnormal FLAIR 
region (B, purple), the isotropic (p) abnormality (C, red) and the anisotropic (q) abnormality (C, 
yellow) is outlined. In figure 1-E summarize above regions of interests in postsurgical T1 post 
contrast image. 
 
FIGURE 2 - Patient overall survival according to q resection ratio 
 
Cox regression survival analysis showed that, patients received q resection ratio more than 
89% had a better overall survival than those received less than 89% of q resection (p = 
0.011).  
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